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ABSTRACT
Background: Coenzyme Q10 (CoQ10) is a lipid-soluble, vitamin-like substance 
found in the hydrophobic interior of the phospholipid bilayer of most cellular mem-
branes. It appears to be involved in the coordinated regulation between oxidative 
stress and antioxidant capacity of heart tissue when the heart is subjected to oxidative 
stress in various pathogenic conditions.
Objective: The objective of the present study was to investigate the effect of 
pretreatment with CoQ10 (100 mg/kg) on isoproterenol (ISO)-induced cardiotoxicity 
and cardiac hypertrophy in rats.
Methods: Albino male Wistar rats (250–300 g) were evenly divided by lottery 
method into 1 of the following 3 groups: the ISO group (olive oil 2 mL/kg orally 
for 18 days and ISO 1 mg/kg IP from days 9–18); the CoQ10 + ISO group (CoQ10 
100 mg/kg orally for 18 days and ISO 1 mg/kg IP from days 9–18); and the con-
trol group (olive oil 2 mL/kg orally for 18 days and water IP from days 9–18). 
Twenty-four hours after the last dose of water or ISO, the rats were anesthetized and 
an ECG was recorded. Blood was withdrawn by retro-orbital puncture for estimation 
of serum creatine kinase-MB (CK-MB) isoenzyme levels, lactate dehydrogenase 
(LDH) levels, and aspartate aminotransferase activities. The animals were euthanized 
using an overdose of ether. The hearts of 6 animals from each group were used for 
estimation of superoxide dismutase (SOD) activity, reduced glutathione (GSH) con-
centration, lipid peroxidation (LPO), malondialdehyde (MDA), and total protein con- 
centration. Histopathology of the 2 remaining hearts in each group was carried out by 
a blinded technician.
Results: A total of 24 rats (8 in each group) were used in this study; all rats 
survived to study end. Compared with the control group, the ISO-treated rats had a 
significant change in heart to body weight ratio (P < 0.001); significant changes in 
the endogenous antioxidants (ie, significantly higher myocardial MDA concentration 
[P < 0.001]; significantly lower myocardial GSH concentration [P < 0.001] and SOD 
activity [P < 0.01]); and significantly higher serum activities of marker enzymes (eg, 
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CK-MB [P < 0.001] and LDH [P < 0.001]). Compared with the ISO group, the 
CoQ10 + ISO group had a significant change in heart to body weight ratio (P < 
0.001); significant changes in the endogenous antioxidants (ie, significantly lower MDA 
concentration [P < 0.05]; significantly higher myocardial GSH concentration [P < 
0.001] and SOD activity [P < 0.05]); and significantly lower serum activities of marker 
enzymes (eg, CK-MB [P < 0.05] and LDH [P < 0.01]).
Conclusion: Pretreatment with CoQ10 (100 mg/kg) for 18 days was associ-
ated with moderate protection against ISO-induced cardiotoxicity and cardiac hyper-
trophy, and with lower myocardial injury by preserving endogenous antioxidants 
and reducing LPO in rat heart. (Curr Ther Res Clin Exp. 2009;70:460–471) © 2009 
Excerpta Medica Inc.
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INTRODUCTION
Cardiac hypertrophy is an adaptive response of the heart muscle to a variety of 
intrinsic and extrinsic stimuli.1 Although hypertrophy of the heart muscle is ini-
tially beneficial during early growth, prolonged hypertrophy is potentially harm-
ful, causing dilated cardiomyopathy and heart failure, which are associated with 
significant morbidity and mortality. Sorting out the molecular mechanisms in-
volved in cardiac hypertrophy has become a primary focus of research to develop 
rational pharmacologic approaches for preventing pathologic changes associated 
with this disease.
Isoproterenol (ISO), a β1-adrenergic agonist, has been reported to be associated 
with oxidative stress in the myocardium, resulting in infarct-like necrosis of the 
heart muscle.2 It is also associated with increases in the concentrations of serum 
and myocardial lipids, which in turn leads to coronary heart disease.3 ISO is 
known to generate free radicals and to stimulate lipid peroxidation (LPO), which 
is a causative factor for irreversible damage to the myocardial membrane,4 and 
thus favors the deposition of myocardial lipids. Enhanced free radical formation 
and lipid peroxide accumulation have been proposed as a possible biochemical 
mechanism for myocardial damage and cardiac hypertrophy during ISO-induced 
myocardial infarction.2
Coenzyme Q10 (CoQ10), or ubiquinone, is a lipid-soluble, vitamin-like substance 
found in the hydrophobic interior of the phospholipid bilayer of most cellular mem-
branes.1 It consists of a quinone head attached to a chain of 9 or 10 isoprene units, 
depending on the mammalian species.5 CoQ10 is known to enhance mitochondrial 
activity related to the synthesis of adenosine triphosphate.6 It also plays a role in the 
inhibition of LPO by scavenging reactive oxygen species (ROS) directly or in con-
junction with α-tocopherol.7 A principal function of CoQ10 is to act as an electron 
carrier between nicotinamide dinucleotide and succinate dehydrogenases and the 
cytochrome system.8 During mitochondrial electron transport, ubiquinone also occurs 
as semiquinone and ubiquinol, the fully reduced form of ubiquinone. Semiquinone 
has a role in the generation of superoxide anions during mitochondrial respiration,9 
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whereas ubiquinol functions as an intracellular antioxidant, presumably by pre-
venting both the initiation and propagation of LPO. CoQ10 appears to be involved 
in the coordinated regulation between oxidative stress and antioxidant capacity of 
heart tissue when the heart is subjected to oxidative stress in various pathogenic 
conditions.10
The objective of the present study was to investigate the effect of pretreatment 
with CoQ10 (100 mg/kg) on ISO-induced cardiotoxicity and cardiac hypertrophy 
in rats.
MATERIALS AND METHODS
Animals
Albino male Wistar rats (250–300 g) were obtained from the National Toxicological 
Centre (Pune, India). The rats were housed under standard conditions: temperature, 
25°C; relative humidity, 60%; and a light–dark cycle of 12 hours. A pellet diet (Chakan 
Oil Mills, Pune, India) and water were provided ad libitum.
All study protocols were approved by the Institutional Animal Ethics Committee 
of the Poona College of Pharmacy (Bharati Vidyapeeth University, Pune, India).
Chemicals
CoQ10 was supplied by Medicines Pvt. Ltd. (Mumbai, India) and the ISO solu-
tion was supplied by Samarth Life Sciences Pvt. Ltd. (Mumbai, India). Epineph-
rine hydrochloride, superoxide dismutase (SOD), and malondialdehyde (MDA) 
were purchased from Sigma Chemical Co. (St. Louis, Missouri). Reduced glutathi-
one (GSH), 5,5'-dithiobis (2-nitrobenzoic acid) (DTNB), and thiobarbituric acid 
(TBA) were obtained from Himedia Laboratories (Mumbai, India). All chemicals 
were analytical grade.
Experimental Procedure
Albino male Wistar rats were evenly divided by lottery method into 1 of the fol-
lowing 3 groups: ISO group (olive oil 2 mL/kg orally for 18 days and ISO 1 mg/kg 
IP from days 9–18); CoQ10 + ISO group (CoQ10 100 mg/kg orally for 18 days and 
ISO 1 mg/kg IP from days 9–18); and the control group (olive oil 2 mL/kg orally for 
18 days and water IP from days 9–18). Olive oil was chosen as the vehicle because 
CoQ10 is soluble in olive oil. The weighed quantity of CoQ10 was dissolved in olive 
oil to make a final solution of 100 mg/mL. The dose of CoQ10 (100 mg/kg) was se-
lected on the basis of previous unpublished pilot dose–response studies. Changes in 
body weight were recorded daily.
Twenty-four hours after the last injection of ISO and vehicle or water, the rats 
were anesthetized using anesthetic ether and an 8-channel ECG was recorded 
(Power Lab System, AD Instruments Pty. Ltd., Bella Vista, Australia). Blood was 
drawn via retro-orbital puncture and centrifuged at 7500 rpm for 15 minutes at 
0°C. Then serum was transferred using a micropipette into microcentrifuge tubes 
(Eppendorf, Tarsons Products Pvt. Ltd., Kolkata, India) and stored at 4°C until 
analyzed.
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The animals were euthanized using an overdose of anesthetic ether, and the hearts 
were isolated and weighed. Hearts from 2 animals in each group were randomly 
selected by lottery method for histopathologic examination. The hearts from the 
remaining 6 animals were cut into small pieces, placed in a chilled sucrose solution 
(0.25 M), and blotted on filter paper. The tissues were then homogenized in 10% 
chilled tris hydrochloride buffer (10 mM, pH 7.4) using a tissue homogenizer 
(Remi Motors, Mumbai, India) and centrifuged at 7500 rpm for 15 minutes at 0ºC 
using a high-speed cooling centrifuge (Eppendorf 5810-R, Eppendorf AG, Hamburg, 
Germany). The clear supernatant was used for the estimation of SOD activity and 
GSH, LPO, MDA, and total protein concentration.
The ECG recording, determination of organ weight, and measurement of myocardial 
MDA and GSH concentrations and SOD activity were done by a single investigator 
(A.E.G.) who was not blinded to treatment group. Serum creatine kinase-MB (CK-MB) 
isoenzyme levels, lactate dehydrogenase (LDH), and aspartate aminotransferase (AST) 
activities were measured by a blinded technician who was not involved in the study.
Serum Parameters
Serum activities of CK-MB, LDH, and AST were measured using an automated 
chemistry analyzer (Micro Lab 300, Merck & Co., Inc., Whitehouse Station, New Jersey) 
and reagent kits (CK-MB [Randox Laboratories Ltd., Antrim, United Kingdom] and 
LDH and AST [Ecoline, Merck Ltd., Mumbai, India]).
Tissue Parameters
Lipid Peroxidation Assay (MDA Concentration)
The LPO assay was used to measure TBA-reactive substances, as described by Slater 
and Sawyer.11 Two milliliters of freshly prepared 10% w/v trichloroacetic acid (TCA) 
was added to 2 mL of the tissue homogenate (supernatant). The mixture was allowed 
to stand in an ice bath for 15 minutes and was then centrifuged at 2500 rpm for 
15 minutes at 0°C. Two milliliters of clear supernatant solution was mixed with 2 mL 
of freshly prepared 0.67% w/v TBA. The resulting solution was heated in a boiling 
water bath for 10 minutes and was then immediately cooled in an ice bath for 5 minutes. 
Color absorbance was measured using an ultraviolet-visible spectrophotometer 
(JASCO-V-530, JASCO Corp., Tokyo, Japan) at 532 nm using 1,1,3,3-tetraethoxypropane 
as a standard.
Estimation of Glutathione Concentration
Myocardial GSH concentration was determined by the method described by Moron 
et al.12 One milliliter of tissue homogenate (supernatant) and 1 mL of 20% w/v TCA 
were mixed and centrifuged at 2500 rpm for 15 minutes at 0°C. Then, 2 mL of 
DTNB (0.6 M) reagent was added to 0.25 mL of supernatant. The final volume was 
increased to 3 mL with phosphate buffer (pH 8.0). The color developed was read at 
412 nm against a blank reagent. Different concentrations (10–50 μg) of standard GSH 
were processed as mentioned previously to construct a standard curve. The amount of 
reduced GSH was expressed as μg/g protein.
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Estimation of Superoxide Dismutase Activity
Myocardial SOD activity was determined using the method of Misra and 
Fridovich,13 in which 0.5 mL of heart homogenate, 0.5 mL of cold distilled water, 
0.25 mL of ice-cold ethanol, and 0.15 mL of ice-cold chloroform were mixed well us-
ing a cyclomixer for 5 minutes and centrifuged at 2500 rpm for 15 minutes at 0°C. 
Then 1.5 mL of carbonate buffer (pH 10.2) and 0.5 mL of 0.4 M ethylenediaminetet-
raacetic acid solutions were added to 0.5 mL of supernatant. The reaction was initiated 
by the addition of 0.4 mL of epinephrine bitartrate (3 mM) and the change in optic 
density per minute was measured at 480 nm against a blank reagent. SOD activity 
was expressed as U/mg protein. The change in optical density per minute at 50% 
inhibition of epinephrine to adrenochrome transition by the enzyme was used as the 
enzyme unit. The calibration curve was prepared using 10 to 125 units of SOD.
Determination of Total Protein Concentration
Myocardial protein concentration was determined using the method of Lowry 
et al.14 Diluted membrane fraction aliquots (0.1 mL) were placed in test tubes. To 
this, 0.8 mL of 0.1 M sodium hydroxide and 5 mL of Lowry C reagent (a freshly pre-
pared mixture of 1 mL of copper sulfate [0.5% w/v] in 1% sodium potassium tartrate 
into 50 mL of sodium carbonate [2% w/v] in 0.1 M sodium hydroxide) was added and 
the solution was allowed to stand for 15 minutes. Then, 0.5 mL of 1 N Folin phenol 
reagent was added and the contents were mixed well by vortex mixer. The color that 
developed was measured at 640 nm against a blank reagent containing distilled water 
instead of sample. Different concentrations (40–200 μg) of standard protein bovine 
serum albumin were processed as mentioned previously for preparation of a standard 
curve. The values were expressed as mg protein/g wet tissue (mg/g).
Histopathologic Studies
Hearts were quickly excised, preserved in 10% formalin, processed, and embedded 
in paraffin. Then 4-μm–thick paraffin sections were cut on glass slides and stained 
with hematoxylin and eosin reagents and observed under a light microscope by an 
independent investigator who was blinded to treatment group to assess myocardial 
injury. Injury was assessed on a 4-point scoring method: 0 = no injury; 1 = mild injury; 
2 = moderate injury; and 3 = severe injury.
Estimation of Organ Weight Ratio
In each group, heart to body weight ratio and left ventricle to body weight ratio were 
determined. Body weight was the weight on the day the rats were euthanized. Heart 
weight was measured after keeping the heart in cold saline and squeezing out the blood.
Statistical Analysis
The statistical analysis was done using GraphPad Prism software version 4.03 
(GraphPad Software Inc., La Jolla, California). Analysis was made using 1-way ANOVA 
followed by post hoc Bonferroni adjustment to control for multiple comparisons. P < 
0.05 was considered statistically significant. It was determined that 6 animals in each 
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group would be needed to make a statistically meaningful comparison of serum 
parameters. Additional animals were added for the histopathologic analysis.
RESULTS
Electrocardiographic Changes
At posttreatment, the mean (SEM) QT interval was significantly higher in the ISO 
group compared with the control group (77.40 [1.00] vs 62.70 [1.00] msec, respec-
tively; P < 0.001); the ST interval was also significantly higher in the ISO group 
(63.00 [1.00] vs 44.08 [0.80] msec; P < 0.001). The QT and ST intervals were 
significantly lower in the CoQ10 + ISO group compared with the ISO group 
(69.00 [0.50], P < 0.01 and 54.10 [1.00], P < 0.001, respectively) (Table I).
Serum Enzyme Activities
Serum CK-MB activity was significantly higher in the ISO group compared with 
the control group (989.2 [70.28] vs 569.8 [73.13] IU/L, respectively; P < 0.001); 
serum LDH activity was also significantly higher in the ISO group (1787.0 [82.55] vs 
953.5 [48.62] IU/L; P < 0.001). Serum CK-MB and LDH activities were significantly 
lower in the CoQ10 + ISO group compared with the ISO group (805.3 [101.9] IU/L, 
P < 0.05 and 1420.3 [98.40] IU/L; P < 0.01). Serum AST activity was signifi-
cantly higher in the ISO group compared with the control group (1058.2 [96.80] vs 
674.6 [97.34] IU/L; P < 0.05). Serum AST activity in the CoQ10 + ISO group was 
not significantly different compared with the ISO group (Table II). 
Myocardial Endogenous Antioxidants
Myocardial MDA concentration was significantly higher in the ISO group com-
pared with the control group (4.42 [0.18] vs 2.68 [0.18] nM MDA/mg protein, re-
spectively; P < 0.001). The MDA concentration was significantly lower in the CoQ10 + 
ISO group compared with the ISO group (3.27 [0.24] nM MDA/mg protein; P < 
0.05). Myocardial GSH concentration was significantly lower in the ISO group com-
pared with the control group (17.79 [1.00] vs 27.50 [0.71] μg GSH/mg protein; P < 
0.001). Myocardial GSH concentration was significantly higher in the CoQ10 + ISO 
group than in the ISO group (26.9 [0.71] μg GSH/mg protein; P < 0.001). Myocar-
dial SOD activity was significantly lower in the ISO group compared with the control 
group (3.59 [0.96] vs 9.49 [1.14] U/mg protein; P < 0.01), whereas myocardial SOD 
activity in the CoQ10 + ISO group was significantly higher than in the ISO group 
(8.85 [0.77] U/mg protein; P < 0.05) (Table III).
Organ Weight Determination
Heart to body weight ratio was significantly higher in the ISO group compared with 
the control group (4.00 [0.09] vs 3.18 [0.08] mg/g, respectively; P < 0.001); left ventricle 
to body weight ratio was also significantly higher in the ISO group (2.04 [0.03] vs 
1.50 [0.09] mg/g; P < 0.05). Heart to body weight ratio was significantly lower in the 
CoQ10 + ISO group compared with the ISO group (3.19 [0.04] mg/g; P < 0.001), as 
was left ventricle to body weight ratio (1.72 [0.06] mg/g; P < 0.05) (Table IV).
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Table I.  Posttreatment ECG findings by treatment group (N = 24). Data are mean (SEM) 
msec.
Interval ISO CoQ10 + ISO Control
QT 77.40 (1.00)* 69.00 (0.50)† 62.70 (1.00)
ST 63.00 (1.00)* 54.10 (1.00)‡ 44.08 (0.80)
ISO = isoproterenol; CoQ10 = coenzyme Q10.
*P < 0.001 versus the control group.
†P < 0.01 versus the ISO group.
‡P < 0.001 versus the ISO group.
Table II.  Posttreatment serum enzyme activities by treatment group (n = 18). Data are 
mean (SEM) IU/L.
Enzyme Activity ISO  CoQ10 + ISO Control
CK-MB 989.2 (70.3)* 805.3 (101.9)† 569.8 (73.1)
LDH 1787.0 (82.6)* 1420.3 (98.4)‡ 953.5 (48.6)
AST 1058.2 (96.8)§ 861.3 (56.6) 674.6 (97.3)
ISO = isoproterenol; CoQ10 = coenzyme Q10; CK-MB = creatine kinase-MB; LDH = lactate dehydrogenase; 
AST = aspartate aminotransferase.
*P < 0.001 versus the control group.
†  P < 0.05 versus the ISO group.
‡  P < 0.01 versus the ISO group.
§  P < 0.05 versus the control group.
Table III.  Myocardial malondialdehyde (MDA) and glutathione (GSH) concentrations and 
superoxide dismutase (SOD) activity by treatment group (n = 18). Data are 
mean (SEM).
Activity ISO CoQ10 + ISO Control
MDA, nM/mg protein 4.42 (0.18)* 3.27 (0.24)† 2.68 (0.18)
GSH, μg/mg protein 17.79 (1.00)* 26.90 (0.71)‡ 27.50 (0.71)
SOD, U/mg protein 3.59 (0.96)§ 8.85 (0.77)† 9.49 (1.14)
ISO = isoproterenol; CoQ10 = coenzyme Q10.
*P < 0.001 versus the control group.
†  P < 0.05 versus the ISO group.
‡  P < 0.001 versus the ISO group.
§  P < 0.01 versus the control group.
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Histopathologic Changes
The ISO-treated rats had marked tissue injury (inflammation, nuclear pyknosis, 
cytoplasmic vacuoles, and cytoplasmic eosinophilia). In the CoQ10 + ISO group, these 
changes were less, though no statistical comparisons were made.
DISCUSSION
Teerlink et al15 suggested that changes in the left ventricular (LV) shape caused due 
to hypertrophy leads to reduction in heart functionality. ISO-induced hypertrophy 
produces increases in the LV cavity that is disproportionate to the weight of the heart. 
Studies in both experimental models and humans have indicated that not only are 
these increases in LV volume important, but changes in the LV geometry may inde-
pendently play an important role in the observed decrease in cardiac performance.16–18 
Other studies have suggested that these alterations in LV geometry may predict im-
pairment of LV function.19,20
Evidence has been found of the involvement of oxidative stress in cardiac diseases, 
including cardiac hypertrophy. ISO-induced cardiac hypertrophy and cardiotoxicity 
serve as a standardized model to study the effects of many drugs on cardiac func-
tion.1 Oxidative stress originating from ISO injection is mediated primarily via 
C1-adrenergic receptors. Stimulation of C1-adrenergic receptors rapidly generates 
ROS as well as depresses total cellular antioxidant capacity.21 Adrenoceptor activation 
produced by ISO may occur through an oxidation mechanism.22 Significant reduc-
tions in cardiac tissue levels of protective antioxidant enzymes, such as SOD and GSH, 
have been observed in ISO-induced cardiotoxicity.1,21,23 Dhalla et al24 reported that 
excess catecholamines affect the calcium transport mechanism primarily via oxidative 
reactions involving free radical–mediated damage and that antioxidants may be indi-
cated for the treatment of stress-induced heart disease.
In a clinical setting, coronary artery disease developes when the vascular supply to 
the heart is impeded. This may impair the supply of oxygenated blood to cardiac 
tissue to such a degree as to induce myocardial ischemia that, if severe and prolonged, 
may induce the death of the myocardial cell. Myocardial infarcts and, less commonly, 
ischemia can also happen if oxygen demand abnormally increases as may occur in severe 
Table IV.  Heart to body weight and left ventricle to body weight ratios by treatment group 
(n = 18). Data are mean (SEM) mg/g.
Ratio ISO CoQ10 + ISO Control
Heart to body weight 4.00 (0.09)* 3.19 (0.04)† 3.18 (0.08)
Left ventricle to body weight 2.04 (0.03)‡ 1.72 (0.06)§ 1.50 (0.09)
ISO = isoproterenol; CoQ10 = coenzyme Q10.
*P < 0.001 versus the control group.
†  P < 0.001 versus the ISO group.
‡  P < 0.05 versus the control group.
§  P < 0.05 versus the ISO group.
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ventricular hypertrophy. In experimental studies, a similar situation of cardiac necro-
sis can be produced by injection of natural or synthetic sympathomimetic in high 
dosages.
The results of our study clearly support that there was increased myocardial injury, 
as indicated by the increase in QT and ST intervals in the ISO-treated group. Admin-
istration of CoQ10 prior to ISO (100 mg/kg) maintained or attenuated the prolonga-
tion of QT and ST intervals close to the values in the control group.
Shimomura et al25 reported that, in rats after running downhill, the serum CK and 
LDH activity of the control group were significantly (P < 0.01 and P < 0.05, respec-
tively) elevated immediately after exercise. However, in the CoQ10-treated group, CK 
activity was at the same level as the sedentary group, indicating that CoQ10 treatment 
was associated with blocking elevated enzyme activity during exercise. Okamoto et al26 
cultured skeletal femoral muscle cells of neonatal rats. Continuous electric field 
stimulation produced rhythmic contraction and relaxation of cells for 4 hours. Lactate 
and lactate dehydrogenase release was elevated after the onset of stimulation, whereas 
intracellular Ca2+ contents increased gradually at relaxation. Addition of 5 μM CoQ10 
appeared to protect the cells against these biochemical changes after stimulation. 
Prince and Rajadurai3 found significant (P < 0.05) increases in the activities of CK 
and LDH in the serum of ISO-treated rats compared with controls. ISO damages 
the myocardial cells, which contain LDH, CK-MB, and AST, resulting in leakage 
of enzymes in the blood. These results are consistent with previous studies.1,21,27,28 In 
the present study, the serum activities of CK-MB, LDH, and AST in the CoQ10-treated 
group were significantly lower than in the ISO-treated group.
It has been reported that ROS are generated due to β1-adrenergic receptor stimula-
tion, while total cellular oxidant capacity is reduced. This event downregulates 
copper-zinc–SOD enzyme activity and protein and mRNA concentration while also 
reducing GSH concentration.29 As a result, integrity of the membrane is lost, reduc-
ing myocyte toxicity and resulting in myocardial necrosis.29,30
The most abundant ROS generated in living cells are superoxide anion and its 
derivatives, particularly the highly reactive and damaging hydroxyl radical, which 
induces peroxidation of cell membrane lipids.31 In this respect, any increase in organ 
SOD activity appears to be beneficial in the event of increased free radical generation. 
In the present study, administration of ISO (1 mg/kg) was associated with a signifi-
cant increase in MDA concentration (an index of LPO) in cardiac tissues and decrease 
in myocardial GSH concentration and SOD activity compared with the control group, 
suggesting an increase in oxidative stress. These results are consistent with previous 
studies that reported the involvement of oxidative stress and LPO in ISO-induced 
cardiac hypertrophy and cardiotoxicity.29,30,32 Administration of CoQ10 improved the 
biochemical markers, indicating decreased oxidative stress, manifested as increased 
GSH concentration and SOD activity with decreased LPO (MDA concentration) com-
pared with ISO treatment alone.
In the present study, histopathologic analysis found inflammation, nuclear pyknosis, 
cytoplasmic vacuoles, and cytoplasmic eosinophilia in the ISO-treated rat hearts. 
Similar findings were reported in earlier studies of ISO-induced cardiotoxicity and 
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cardiac hypertrophy.5,28–30 In the present study, histopathologic analysis revealed less 
damage in the CoQ10 + ISO group than in the ISO group.
Limitations
Some experiments and the drug administration were not blinded. However, serum 
determinations and histopathologic assessments were blinded.
CONCLUSION
Pretreatment with CoQ10 (100 mg/kg) for 18 days was associated with moderate protec-
tion against ISO-induced cardiotoxicity and cardiac hypertrophy, and with lower myo-
cardial injury by preserving endogenous antioxidants and reducing LPO in rat heart.
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